Back to top

Analyst Blog

Impax Laboratories, Inc. (IPXL - Snapshot Report) announced that it has started shipping the authorized generic version of Sanofi’s (SNY - Analyst Report) Renvela (800 mg) under its settlement agreement with the latter. The drug is approved for the control of serum phosphorus in patients suffering from chronic kidney disease (CKD) and dependent on dialysis.

We note that Impax’s settlement agreement with Sanofi allows it to sell generic versions of two other products − Renagel and Renvela (for oral suspension) starting on Sep 16, 2014, pending U.S. Food and Drug Administration (FDA) approval for its abbreviated new drug applications (ANDAs) for these products.

Meanwhile, Impax is looking to get its ANDA for generic Renvela approved by the FDA. Approval would allow the company to launch its generic version later this year.

Our Take

The launch of the authorized generic version of Renvela is an important event for Impax. Renvela’s U.S. sales were about $907 million in the 12 months ended Feb 2014, as per IMS Health.

Impax expects the sale of authorized generic Renvela to generate net profits of approximately $50 million−$70 million in 2014.

Meanwhile, Impax’s Rytary is under FDA review for the symptomatic treatment of Parkinson's disease (PD). The company is looking for commercialization partners for Rytary outside the U.S.

We expect investor focus to remain on further updates from the company especially on the Hayward manufacturing facility.  

Impax carries a Zacks Rank #2 (Buy). Some better-ranked stocks in the health care sector include Mallinckrodt plc (MNK - Snapshot Report) and Actavis plc (ACT - Analyst Report). Both stocks carry a Zacks Rank #1 (Strong Buy).

Read the Full Research Report on SNY
Read the Full Research Report on IPXL
Read the Full Research Report on MNK
Read the Full Research Report on ACT


Zacks Investment Research

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%